Apr 10 |
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
|
Apr 8 |
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
|
Apr 5 |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
Apr 3 |
Crinetics, Syndax gain amid pitch at Sohn charity conference (update)
|
Mar 28 |
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
|
Mar 28 |
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
|
Mar 28 |
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
|
Mar 26 |
FDA grants priority review for Syndax leukemia drug, sets action date
|
Mar 26 |
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
|
Mar 18 |
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
|